Impact Factor 3.831

Frontiers journals are at the top of citation and impact metrics

Correction ARTICLE

Front. Pharmacol., 09 October 2018 | https://doi.org/10.3389/fphar.2018.01128

Corrigendum: Ulinastatin Inhibits Osteoclastogenesis and Suppresses Ovariectomy-Induced Bone Loss by Downregulating uPAR

Jun-ming Huang, Ran-yue Ren, Yuan Bao, Jia-chao Guo, Wei Xiang, Xing-zhi Jing, Jia Shi, Guo-xiang Zhang, Long Li, Yong Tian, Hao Kang* and Feng-jin Guo*
  • Department of Orthopedics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

A Corrigendum on
Ulinastatin Inhibits Osteoclastogenesis and Suppresses Ovariectomy-Induced Bone Loss by Downregulating uPAR

by Huang, J., Ren, R., Bao, Y., Guo, J., Xiang, W., Jing, X., et al. (2018). Front. Pharmacol. 9:1016. doi: 10.3389/fphar.2018.01016

In the original article, there was a mistake in Figure 1 as published. The images used for the group of OVX+U were from a different study. The corrected Figure 1 appears below. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.

FIGURE 1
www.frontiersin.org

Figure 1. Ulinastatin inhibits bone loss induced by OVX. (A) μ-CT images of the trabecular bone of distal femoral metaphysis from the SHAM, OVX, and OVX + ulinastatin groups. (B) The trabecular structural parameters of the distal femur: trabecular bone volume/tissue volume (BV/TV), trabecular number (Tb.N), trabecular thickness (Tb.Th), and trabecular separation (Tb.Sp). Data are presented as means ± SD. n = 10 and *P < 0.05.

The original article has been updated.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Keywords: ulinastatin, uPAR, osteoclast, MAPKs, NF-kB, RANKL, osteoporosis

Citation: Huang J, Ren R, Bao Y, Guo J, Xiang W, Jing X, Shi J, Zhang G, Li L, Tian Y, Kang H and Guo F (2018) Corrigendum: Ulinastatin Inhibits Osteoclastogenesis and Suppresses Ovariectomy-Induced Bone Loss by Downregulating uPAR. Front. Pharmacol. 9:1128. doi: 10.3389/fphar.2018.01128

Received: 07 September 2018; Accepted: 14 September 2018;
Published: 09 October 2018.

Edited and reviewed by: Wolff Mayer Kirsch, Loma Linda University Medical Center (LLUMC), United States

Copyright © 2018 Huang, Ren, Bao, Guo, Xiang, Jing, Shi, Zhang, Li, Tian, Kang and Guo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Hao Kang, kanghao100@vip.sina.com
Feng-jin Guo, fguo@tjh.tjmu.edu.cn

These authors have contributed equally to this work